EGA
BSTC

Eagle Global Advisors’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Eagle Global Advisors’s Portfolio BSTC Stock Details BSTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-9,946
Closed -$492K – 406
2017
Q2 		$492K Hold
9,946
– – 0.01% 219
2017
Q1 		$545K Buy
9,946
+1,210
+14% +$64.1K 0.01% 203
2016
Q4 		$487K Buy
+8,736
New +$420K 0.01% 215

Other funds holding BSTC

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Eagle Global Advisors's BSTC Position: Q3 2017 in Review

Eagle Global Advisors sold out of BioSpecifics Technologies Corp. (BSTC) in Q3 2017, closing a stake of 9,946 shares — an estimated $492K sold.

Eagle Global Advisors first reported a position in BSTC in Q4 2016 and held it in 3 quarters. The position peaked at $545K in Q1 2017. 87 funds tracked by Wall St. Rank hold BSTC as of Q3 2017.

  • Eagle Global Advisors reported no remaining BioSpecifics Technologies Corp. position as of Q3 2017 after selling out during the quarter.
  • Eagle Global Advisors sold 9,946 BioSpecifics Technologies Corp. shares in Q3 2017, an estimated $492K.
  • Eagle Global Advisors first reported a position in BioSpecifics Technologies Corp. in Q4 2016 and held it in 3 quarters.
  • Eagle Global Advisors's BioSpecifics Technologies Corp. position peaked at $545K in Q1 2017.
  • 87 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q3 2017.

Based on Eagle Global Advisors's 13F filing for Q3 2017, filed 13 Nov 2017.